Purpose: Examining the prevalence, incidence and persistence of use of etanercept and adalimumab in Norway during 2005-2009.
Methods: We retrieved data from the nationwide Norwegian Prescription Database (NorPD) for all individuals who were dispensed etanercept or adalimumab from pharmacies during 2005-2009. The NorPD covers the total Norwegian population in ambulatory care. Key measurements were one-year prevalence, incidence rate and persistence (minimum refill).
Results: The one-year prevalence for etanercept and adalimumab was 1.59‰ (n = 3840) for men and 1.85‰ (n = 4483) for women in 2009, an increase from 0.76‰ (n = 1752) for men and 1.21‰ (n = 2830) for women from 2005. The prevalence increased during the entire study time in all ages, with the highest prevalence for both genders among those aged 50-69. A total of 7786 individuals started therapy with etanercept or adalimumab during 2005-2009. Annual incidence of new users increased with 23.6% from 2005 to 2009. Sixty one percent of new users redeemed etanercept as the first drug, and 39% redeemed adalimumab. Sixty seven percent of all individuals who received etanercept or adalimumab in 2005 refilled their prescription at least once each of the following 4 years.
Conclusions: Both prevalence and incidence of use of etanercept and adalimumab increased in Norway during 2005-2009. A high proportion of the individuals redeemed prescriptions regularly over 5 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pds.2091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers.
Biomedicines
December 2024
Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain.
: Psoriasis is a skin disease characterized by the presence of erythematous, scaly plaques on the extensor surfaces of the body. Treatment varies according to the stage of the disease, with the most severe cases being treated with biologic treatments that differ in efficacy and persistence over time. This study aimed to evaluate the 10-year persistence of biologic drugs (adalimumab, etanercept, infliximab and ustekinumab) in the treatment of moderate-to-severe plaque psoriasis.
View Article and Find Full Text PDFIncidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea.
Rheumatology (Oxford)
January 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Objective: To describe the incidence rates of inflammatory bowel disease (IBD) and tuberculosis (TB) in Korean patients with ankylosing spondylitis receiving biologics.
Methods: Data from a Korean claims database between 2010 and 2021 was used to calculate crude incidence rates of TB and IBD using number of events and total patient-years (PYs).
Results: Overall, 43 643 and 43 396 patients were included in TB and IBD cohorts.
Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline.
J Dermatolog Treat
December 2025
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Purpose: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly developing, painful ulcers. This study explores the potential of spesolimab, an anti-IL-36R antibody, as a therapeutic option for refractory PG.
Materials And Methods: We report a case of a 48-year-old male with refractory PG who failed to respond to etanercept and adalimumab.
Cross-sectional patient survey of biological medicine users in Finland to investigate the types of guidance needed by patients in order to carry out their treatment successfully.
BMJ Open
January 2025
Oriola Finland Oy, Espoo, Uusimaa, Finland
Background: The use of new biological medicines as standard treatment is expected to increase substantially and cover new therapeutic indications in the near future. Interchange of biological medicines in pharmacies increases the need for patient guidance.
Objectives: The study aims to gain a patient perspective on biological medicine users' needs and wishes regarding patient guidance by exploring what kind of information patients wish to receive and to further investigate the potential differences in needs between originator biological medicine users and biosimilar users.
A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system.
Arch Dermatol Res
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1150 NW 14th Street, Miami, FL, 33136, USA.
Pityriasis rosea (PR) is an acute exanthematous disease with an uncertain physiopathology, increasingly recognized as potentially drug induced. This study aims to investigate medication triggers associated with PR by analyzing cases reported in the FDA Adverse Event Reporting System (FAERS) database. A retrospective review of 343 PR cases reported in the FAERS database from January 1, 1998, to March 31, 2024, was conducted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!